Iterum Therapeutics Focused On First Oral Penem

13 Jul 2017

• By John Davis

Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.

Urinary Tract Infections (UTIs) are to be targeted by sulopenem • Source: Shutterstock

Dublin, Ireland and Chicago, Illinois-based Iterum Therapeutics Ltd., set up in 2015 by a small team of biotech executives and a VC syndicate, has in its sights the development of the first penem antibiotic that can be administered orally, sulopenem.

The compound can also be administered intravenously and has a broad spectrum of activity, making it potentially useful for both...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

11 Jun 2025

• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Sweden’s Hansa Slims Down Ahead of Key Readouts

27 May 2025

• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

End Is Nigh For 4SC After EMA’s No For Kinselby

21 May 2025

• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

12 Jun 2025

• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.